| 1.53 Data as of May 24 |  -0.04 / -2.55%Today’s Change | 1.11 Today|||52-Week Range 3.30 | +15.04% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Medical Specialties | MARKET CAP $154.2M |
Company Description
Zogenix, Inc. is a pharmaceutical that engaged in company commercializing and developing products for the treatment of central nervous system disorders and pain with novel drug delivery platforms. The company's product portfolio includes: Sumavel DosePro, Zohydro and Relday. The Sumavel DosePro product offers fast-acting, easy-to-use subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache. The Zohydro product is a 12-hour extended-release formulation of hydrocodone without acetominophen for the treatment of moderate to severe chronic pain requiring around-the-clock opioid therapy. The Relday product is a proprietary, long-acting injectable formulation of risperidone using durect's SABER controlled-release formulation technology in combination with its DosePro needle-free, subcutaneous drug delivery system. Zogenix was founded by Stephen J. Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. Rigby and John J. Turanin on May 11, 2006 and is headquartered in San Diego, CA.
Employees
Shareholders
| Mutual fund holders | 33.21% |
| Individual stakeholders | 27.33% |
| Other institutional | 15.87% |
Top Executives
| Cam L. Garner, MBA | Chairman |
| Stephen J. Farr, PhD | President & Director |
| Roger L. Hawley, CPA | Chief Executive Officer & Director |
| Ann D. Rhoads, MBA | CFO, Secretary, Treasurer & Executive VP |
| Jeff D. Durflinger | VP-Technical Operations & Product Supply |
.
